COMET Trial Now Recruiting to Study Active Surveillance in Low-risk DCIS

COMET Trial Now Recruiting to Study Active Surveillance in Low-risk DCIS
A new breast cancer clinical trial called COMET (NCT02926911) is now enrolling participants to evaluate the risks and benefits of a monitoring approach vs. a full-mode attack with surgery and other therapeutic approaches in women with low-risk ductal carcinoma in situ (DCIS). DCIS is a condition characterized by the presence of abnormal (cancer-like) cells inside the breast milk ducts, and is considered the earliest form of breast cancer. The cells are confined to the ducts, however, and have not spread into the surrounding breast tissue, so it is considered noninvasive. The American Cancer Society estimates that around 60,000 cases of DCIS are diagnosed each year in the United States, accounting for one out of every five new breast cancer cases. While DCIS is not considered life-threatening, 20 to 30 percent of women with this condition will eventually develop an invasive breast cancer later on. So if DCIS is not invasive but may become invasive in the future, what should women do who are diagnosed with DCIS? Most patients with low-risk DCIS follow guideline concordant care (GCC) and undergo surgery. The treatment options include lumpectomies (a procedure in which a lump is removed from the breast) often followed by radiation. Some, however, have full mastectomies (removal of both breasts). Others may also take anti-cancer therapies, such as tamoxifen, for several years. But women who undergo surgical management of DCIS often report persistent pain at the surgical site and see it as a disability and cause of psychological distress. Another option for these women is to undergo active surveillance, an option offered to low-risk patients that consist
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.